NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
University of Pittsburgh
OHSU Knight Cancer Institute
Ospedale Policlinico San Martino
Hoosier Cancer Research Network